Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186968 | 0.81 | ACACB (0.39) | — | |
| SCHEMBL2536759 | 0.81 | BACE1 (0.31) | — | |
| SCHEMBL29161616 | 0.78 | CDK4 (0.32) | KDR | |
| SCHEMBL1039192 | 0.78 | ACACB (0.41) | L3MBTL1 | |
| SCHEMBL590655 | 0.77 | MAP2K1 (0.42) | KDRKDM4ESCN8ASCN10A | |
| SCHEMBL18914245 | 0.77 | ALDH1A1 (0.39) | KDRKDM4E | |
| SCHEMBL3377603 | 0.77 | SMN1; SMN2 (0.43) | KDRKDM4ESCN8ASCN10A | |
| SCHEMBL3658413 | 0.77 | HTR2C (0.44) | — | |
| SCHEMBL29079055 | 0.77 | ACACB (0.42) | KDRGSK3B | |
| SCHEMBL16553455 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2164840-A2 | MODULATORS OF CFTR | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166516-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | L3MBTL1 4074/4885KDR 4058/4885KDM4E 4281/4885 |
| US-20150031708-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | L3MBTL1 4074/4885KDR 4058/4885KDM4E 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.